Quetiapine Fumarate Tablet
Product Images NDC 80425-0413

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 80425-0413). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Quetiapine Fumarate 100mg #30 (Quetiapine Fumarate 100mg Ndc 80425 0413 01)

Quetiapine fumarate 100 mg oral tablet label from Advanced Rx of Tennessee, LLC. The label includes dosage strength, lot information, expiration date, and comparison to Seroquel with an NDC reference. Storage instructions specify 20°-25°C (68°-77°F). The label also features a barcode, a printed #30 indicating quantity, and a note that the drug is Rx only.*

FDA Label Image

Quetiapine Fumarate 100mg #60 (Quetiapine Fumarate 100mg Ndc 80425 0413 02)

Quetiapine fumarate 100 mg tablet packaging label from Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0413-02, compares to SEROQUEL, and shows storage instructions and lot/expiration information. It is marked Rx Only with a barcode and batch details.*

FDA Label Image

Quetiapine Fumarate 100mg #90 (Quetiapine Fumarate 100mg Ndc 80425 0413 03)

Label for Quetiapine fumarate 100 mg tablet from Advanced Rx of Tennessee, LLC, Nashville, TN. The label includes storage instructions (20-25°C), a barcode, and references a comparison to SEROQUEL. It specifies prescription use (Rx Only) and mentions the lot number and expiration date as placeholders.*

FDA Label Image

Molecular Structure (E6dd3e1f 31d1 4d58 A717 D0bb4a4b8b6d 01)

Chemical structure diagram of quetiapine fumarate showing the molecular arrangement of atoms including the quetiapine moiety and fumarate ions.*

FDA Label Image

Figure 1 (E6dd3e1f 31d1 4d58 A717 D0bb4a4b8b6d 02)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time in weeks. Two lines compare relapse rates for patients treated with QTP+LI/VAL (quetiapine fumarate plus lithium and valproate) versus PLA+LI/VAL (placebo plus lithium and valproate). The y-axis represents the percentage of patients with relapse, while the x-axis shows time in weeks up to 100.*

FDA Label Image

Figure 2 (E6dd3e1f 31d1 4d58 A717 D0bb4a4b8b6d 03)

Kaplan-Meier curve showing the proportion of patients with relapse over time (weeks), comparing two treatment groups: QTP + LI/VAL (dashed line) and PLA + LI/VAL (solid line). The graph depicts a lower relapse proportion for the QTP + LI/VAL group compared to PLA + LI/VAL over approximately 100 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.